Canntab Therapeutics Limited: Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp. Company" or " Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2 nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00. Canntab has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the Company and MediPharm Labs in June, 2020.